Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10920892 | Radiotherapy and Oncology | 2005 | 7 Pages |
Abstract
Treatment of FaDu hSCC with the anti-EGFR mAb C225 resulted in a significant prolongation of tumour growth delay after single dose and fractionated irradiation. In contrast to previous results on the EGFR-TK inhibitor BIBX1382BS, this prolongation of growth delay translated into a slight but significant improvement of local tumour control. The data indicate that different classes of EGFR inhibitors may have different potential to improve the outcome of radiotherapy in the same tumour model.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
M. Krause, C. Schütze, C. Petersen, N. Pimentel, F. Hessel, A. Harstrick, M. Baumann,